| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 90.4 | 84.1 |
| Gross profit | 31.9 | 35.5 |
| Profit before tax | -14.0 | -7.5 |
| Net income | -13.2 | -6.6 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +7.5% |
|---|---|
| Gross margin | 35.3% |
| Operating margin | -24.9% |
10-Q filed with the SEC, NASDAQ: FLGT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Fulgent Genetics, Inc.: key numbers
- Share price
- $24.21Close, Nov 17
- Market cap
- $676M
- Shares outstanding
- 27.94MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Fulgent Genetics, Inc.
All →Fulgent Genetics Financial Results
Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.
- Term
- Q3 2026
“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer
“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
Paul Kim, Chief Financial Officer